# Supplemental Digital Content 11. Solicited systemic reactions after any dose of CYD-TDV or Tdap vaccine – SafAS

|  |  |  |
| --- | --- | --- |
|  | **All** | **Dengue-seropositive** |
|  | **Concomitant (N=338)** | **Sequential (N=342)** | **Concomitant (N=314)** | **Sequential (N=315)** |
| **Participants experiencing ≥1:** | **Maximum intensity** | **n/M** | **%** | **95% CI** | **n/M** | **%** | **95% CI** | **n/M** | **%** | **95% CI** | **n/M** | **%** | **95% CI** |
| **Fever** | **Any** | 21/338 | 6.2 | 3.9, 9.3 | 30/340 | 8.8 | 6.0, 12.4 | 18/314 | 5.7 | 3.4, 8.9 | 28/315 | 8.9 | 6.0, 12.6 |
|  | **Grade 3** | 2/338 | 0.6 | 0.1, 2.1 | 3/340 | 0.9 | 0.2, 2.6 | 2/314 | 0.6 | 0.1, 2.3 | 2/315 | 0.6 | 0.1, 2.3 |
| **Headache** | **Any** | 89/338 | 26.3 | 21.7, 31.4 | 115/341 | 33.7 | 28.7, 39.0 | 83/314 | 26.4 | 21.6, 31.7 | 108/315 | 34.3 | 29.1, 39.8 |
|  | **Grade 3** | 3/338 | 0.9 | 0.2, 2.6 | 3/341 | 0.9 | 0.2, 2.5 | 3/314 | 1.0 | 0.2, 2.8 | 3/315 | 1.0 | 0.2, 2.8 |
| **Malaise** | **Any** | 91/338 | 26.9 | 22.3, 32.0 | 111/341 | 32.6 | 27.6, 37.8 | 85/314 | 27.1 | 22.2, 32.3 | 104/315 | 33.0 | 27.8, 38.5 |
|  | **Grade 3** | 3/338 | 0.9 | 0.2, 2.6 | 3/341 | 0.9 | 0.2, 2.5 | 3/314 | 1.0 | 0.2, 2.8 | 3/315 | 1.0 | 0.2, 2.8 |
| **Myalgia** | **Any** | 74/338 | 21.9 | 17.6, 26.7 | 100/341 | 29.3 | 24.5, 34.5 | 69/314 | 22.0 | 17.5, 27.0 | 93/315 | 29.5 | 24.5, 34.9 |
|  | **Grade 3** | 4/338 | 1.2 | 0.3, 3.0 | 4/341 | 1.2 | 0.3, 3.0 | 4/314 | 1.3 | 0.3, 3.2 | 4/315 | 1.3 | 0.3, 3.2 |
| **Asthenia** | **Any** | 67/338 | 19.8 | 15.7, 24.5 | 94/341 | 27.6 | 22.9, 32.6 | 63/314 | 20.1 | 15.8, 24.9 | 87/315 | 27.6 | 22.8, 32.9 |
|  | **Grade 3** | 4/338 | 1.2 | 0.3, 3.0 | 3/341 | 0.9 | 0.2, 2.5 | 3/314 | 1.0 | 0.2, 2.8 | 3/315 | 1.0 | 0.2, 2.8 |

CI, confidence interval; M, number of participants with available data for the relevant endpoint; n, sample number; SafAS, Safety Analysis Set